Association of amyloid angiopathy with microbleeds in logopenic progressive aphasia: an imaging-pathology study.
atypical Alzheimer’s disease
cerebral amyloid angiopathy
logopenic progressive aphasia
magnetic resonance imaging
microbleeds
positron emission tomography
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
07
10
2020
accepted:
09
10
2020
pubmed:
18
10
2020
medline:
13
8
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
Cerebral microbleeds (MB) and superficial siderosis (SS) are frequent neuroimaging findings in patients with logopenic progressive aphasia (LPA), often with frontal lobe predilection. Cerebral amyloid angiopathy (CAA) is hypothesized to be the major pathologic determinant of MB/SS in these patients; however, neuroimaging-pathologic data are limited. All patients who had been prospectively recruited by the Neurodegenerative Research Group at the Mayo Clinic (Rochester, MN) between 2010 and 2015 and met the following inclusion criteria were included: (i) received an antemortem LPA diagnosis, (ii) had a gradient-recalled echo T2*-weighted magnetic resonance imaging (MRI) performed, (iii) died and completed a brain autopsy. Demographic, genetic, neuroimaging, and clinical and pathologic characteristics were compared between patients with/without MB/SS. Two-tailed Fisher exact and Wilcoxon rank sum tests were used for comparison of categorical and continuous variables, respectively. Thirteen patients met inclusion criteria, six (46%) had MB/SS on MRI. Moderate/severe CAA was associated with the presence of MB/SS (p = 0.029). As expected, MB/SS most frequently involved the frontal lobes, followed by the parietal lobes. No clear associations were found between regional MB/SS distribution and regional distribution of CAA or hypometabolism on [ The presence of MB/SS is a strong indicator of underlying moderate/severe CAA in LPA, although the biological mechanisms underlying the topographic distribution of MB/SS remain unclear.
Sections du résumé
BACKGROUND AND PURPOSE
Cerebral microbleeds (MB) and superficial siderosis (SS) are frequent neuroimaging findings in patients with logopenic progressive aphasia (LPA), often with frontal lobe predilection. Cerebral amyloid angiopathy (CAA) is hypothesized to be the major pathologic determinant of MB/SS in these patients; however, neuroimaging-pathologic data are limited.
METHODS
All patients who had been prospectively recruited by the Neurodegenerative Research Group at the Mayo Clinic (Rochester, MN) between 2010 and 2015 and met the following inclusion criteria were included: (i) received an antemortem LPA diagnosis, (ii) had a gradient-recalled echo T2*-weighted magnetic resonance imaging (MRI) performed, (iii) died and completed a brain autopsy. Demographic, genetic, neuroimaging, and clinical and pathologic characteristics were compared between patients with/without MB/SS. Two-tailed Fisher exact and Wilcoxon rank sum tests were used for comparison of categorical and continuous variables, respectively.
RESULTS
Thirteen patients met inclusion criteria, six (46%) had MB/SS on MRI. Moderate/severe CAA was associated with the presence of MB/SS (p = 0.029). As expected, MB/SS most frequently involved the frontal lobes, followed by the parietal lobes. No clear associations were found between regional MB/SS distribution and regional distribution of CAA or hypometabolism on [
CONCLUSIONS
The presence of MB/SS is a strong indicator of underlying moderate/severe CAA in LPA, although the biological mechanisms underlying the topographic distribution of MB/SS remain unclear.
Identifiants
pubmed: 33068458
doi: 10.1111/ene.14594
pmc: PMC8174551
mid: NIHMS1699838
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
670-675Subventions
Organisme : NIH HHS
ID : NIRG-12-242215
Pays : United States
Organisme : NIH HHS
ID : R01-AG50603
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG050603
Pays : United States
Organisme : NIH HHS
ID : R01-DC10367
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC010367
Pays : United States
Informations de copyright
© 2020 European Academy of Neurology.
Références
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
Alzheimers Dement. 2013 Oct;9(5 Suppl):S116-23
pubmed: 23375568
Alzheimers Dement. 2014 Jan;10(1):62-6
pubmed: 23562427
Brain. 2019 Aug 1;142(8):2483-2491
pubmed: 31199475
JAMA Neurol. 2016 Aug 1;73(8):934-43
pubmed: 27271785
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Acta Neuropathol. 2010 Mar;119(3):291-302
pubmed: 19937043
Neurology. 2004 Jul 13;63(1):16-21
pubmed: 15249604
J Alzheimers Dis. 2015;45(4):1109-17
pubmed: 25649655
Neurology. 2020 Jan 14;94(2):e190-e199
pubmed: 31801832
JAMA Neurol. 2016 Jun 1;73(6):632-5
pubmed: 27089544
Neurology. 1996 Jun;46(6):1592-6
pubmed: 8649554
Acta Neuropathol. 2017 Mar;133(3):409-415
pubmed: 27771772
Brain. 2016 Nov 1;139(11):2957-2969
pubmed: 27591113
Arch Neurol. 2008 Jun;65(6):790-5
pubmed: 18541799
Eur Neurol. 2015;74(3-4):158-61
pubmed: 26447814
Neurology. 2012 Aug 21;79(8):763-9
pubmed: 22875093